Review



braf v600e mutated melanoma cell lines a375  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC braf v600e mutated melanoma cell lines a375
    Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and <t>A375</t> S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).
    Braf V600e Mutated Melanoma Cell Lines A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5055 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf v600e mutated melanoma cell lines a375/product/ATCC
    Average 99 stars, based on 5055 article reviews
    braf v600e mutated melanoma cell lines a375 - by Bioz Stars, 2026-06
    99/100 stars

    Images

    1) Product Images from "Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma"

    Article Title: Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms26199794

    Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and A375 S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).
    Figure Legend Snippet: Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and A375 S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).

    Techniques Used: Phospho-proteomics, Western Blot, Control

    Cell viability and cell cycle. Effects of the combination of ERKi/BRAFi on the viability ( A , B ) and cell cycle ( C ) of melanoma cells. ( A ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) of three independent experiments, each measured in quadruplicate and normalized to the untreated control. ( B ) Shown is the synergism analysis of 451LU (S and R), Mel1617 (S and R) and A375 (S and R) treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. (red = antagonistic, green = synergistic). ( C ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with PLX4032 (1 or 5 µM), GDC0994 (1 and 5 µM) and the combination (1 µM + 1 µM or 5 µM + 5 µM) for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate.
    Figure Legend Snippet: Cell viability and cell cycle. Effects of the combination of ERKi/BRAFi on the viability ( A , B ) and cell cycle ( C ) of melanoma cells. ( A ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) of three independent experiments, each measured in quadruplicate and normalized to the untreated control. ( B ) Shown is the synergism analysis of 451LU (S and R), Mel1617 (S and R) and A375 (S and R) treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. (red = antagonistic, green = synergistic). ( C ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with PLX4032 (1 or 5 µM), GDC0994 (1 and 5 µM) and the combination (1 µM + 1 µM or 5 µM + 5 µM) for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate.

    Techniques Used: Control, Staining, Flow Cytometry

    Colony formation assay. ( A ) The cell lines 451LU S, 451LU R, Mel1617 S and Mel1617 R and ( B ) the cell lines A375 S, A735 R, SKMel19 S and SKMel19 R were seeded and then treated for 10 consecutive days with PLX4032 (5 µM), GDC0994 (5 µM) or the combination. The colonies were fixed with 4% paraformaldehyde visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.
    Figure Legend Snippet: Colony formation assay. ( A ) The cell lines 451LU S, 451LU R, Mel1617 S and Mel1617 R and ( B ) the cell lines A375 S, A735 R, SKMel19 S and SKMel19 R were seeded and then treated for 10 consecutive days with PLX4032 (5 µM), GDC0994 (5 µM) or the combination. The colonies were fixed with 4% paraformaldehyde visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Techniques Used: Colony Assay, Staining

    Effect on double-resistant cell lines. ( A ) Mel1617 RR cells were treated with PLX4032+GDC0973 (up to 20 µM PLX4032 and 5 µM GDC0973), GDC0994 (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) normalized to the untreated control. The bottom panel shows the corresponding synergism analysis. (red = antagonistic, green = synergistic). ( B ) A375 RR and Mel1617 RR cells were treated with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) and the combination thereof for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate. ( C ) The cell lines A375 RR and Mel1617 RR were seeded and then treated for 10 consecutive days with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) or their combination. The colonies were fixed with 4% paraformaldehyde and visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.
    Figure Legend Snippet: Effect on double-resistant cell lines. ( A ) Mel1617 RR cells were treated with PLX4032+GDC0973 (up to 20 µM PLX4032 and 5 µM GDC0973), GDC0994 (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) normalized to the untreated control. The bottom panel shows the corresponding synergism analysis. (red = antagonistic, green = synergistic). ( B ) A375 RR and Mel1617 RR cells were treated with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) and the combination thereof for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate. ( C ) The cell lines A375 RR and Mel1617 RR were seeded and then treated for 10 consecutive days with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) or their combination. The colonies were fixed with 4% paraformaldehyde and visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Techniques Used: Control, Staining, Flow Cytometry



    Similar Products

    braf v600e mutated melanoma cell lines a375  (ATCC)
    99
    ATCC braf v600e mutated melanoma cell lines a375
    Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and <t>A375</t> S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).
    Braf V600e Mutated Melanoma Cell Lines A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf v600e mutated melanoma cell lines a375/product/ATCC
    Average 99 stars, based on 1 article reviews
    braf v600e mutated melanoma cell lines a375 - by Bioz Stars, 2026-06
    99/100 stars
    		  Buy from Supplier
    human braf gene v600e mutation detection kit  (Amoy Diagnostics)
    86
    Amoy Diagnostics human braf gene v600e mutation detection kit
    Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and <t>A375</t> S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).
    Human Braf Gene V600e Mutation Detection Kit, supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human braf gene v600e mutation detection kit/product/Amoy Diagnostics
    Average 86 stars, based on 1 article reviews
    human braf gene v600e mutation detection kit - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    bcpap homozygous mutated braf v600e cell line  (DSMZ)
    95
    DSMZ bcpap homozygous mutated braf v600e cell line
    (A) Immunobloting of pPDPK1, PDPK1, pMEK, and MEK in thyroid cancer lines: papillary thyroid cancer (PTC, brown color) (TPC1), follicular thyroid cancer (FTC, blue color) (FTC-133 and FTC-236), poorly differentiated thyroid cancer (PDTC, green color) (BCPAP), BRAF wild type anaplastic thyroid cancer (ATC) (red color) (C643 and THJ29T), BRAF <t>V600E–mutant</t> ATC (8505C, SW1736, and THJ16T), and HEK293 cells using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to HEK293 cells. (B) Immunoblotting of phosphoPDPK1, total PDPK1 in untreated and dabrafenib (Dab) and trametinib–treated patient derived ATC and normal thyroid tissues using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to normal thyroid tissue. (C–D) Dose-dependent inhibition of cell proliferation with BX795 treatment in 8505C and SW1736 cells after 48 h. (E–F) Dose-dependent inhibition of cell proliferation with Dab treatment in 8505C and SW1736 ATC cells after 48 h. (G–H) Analysis of the combination index (CI) using the CompuSyn software for BX795, Dab, and their combination in BRAF V600E–mutant ATC cell lines. CI < 1 indicates synergism, and fa denotes fraction affected. (I–J) The effect of BX795 (2.5 µM), Dab (2.5 µM), and their combination on cellular proliferation in 8505C and SW1736 cells after 48 h. (K–L) Colony-formation assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using ImageJ. (M–N) Cellular migration as measured with a wound-healing assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using the ImageJ software. (O–P) Concentration-dependent effects of BX795 treatment on proliferation of patient-derived ATC cells (ATC01 and ATC02). ATC01 was derived from a treatment-naïve patient tumor positive for BRAF V600E mutation, and ATC02 was derived from a residual tumor in a patient with an exceptional treatment response to Dab and trametinib, and the tumor was positive for BRAF V600E mutation. (Q–R) The effects of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on the proliferation of patient-derived ATC cells (ATC01 and ATC02). (S) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on ATC spheroids in BRAF V600E–mutant in the 8505C and SW1736 cell lines. (T) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on patient-derived ATC spheroids (ATC01 and ATC02). All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
    Bcpap Homozygous Mutated Braf V600e Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcpap homozygous mutated braf v600e cell line/product/DSMZ
    Average 95 stars, based on 1 article reviews
    bcpap homozygous mutated braf v600e cell line - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    braf mutation test  (Antech Diagnostics)
    86
    Antech Diagnostics braf mutation test
    (A) Immunobloting of pPDPK1, PDPK1, pMEK, and MEK in thyroid cancer lines: papillary thyroid cancer (PTC, brown color) (TPC1), follicular thyroid cancer (FTC, blue color) (FTC-133 and FTC-236), poorly differentiated thyroid cancer (PDTC, green color) (BCPAP), BRAF wild type anaplastic thyroid cancer (ATC) (red color) (C643 and THJ29T), BRAF <t>V600E–mutant</t> ATC (8505C, SW1736, and THJ16T), and HEK293 cells using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to HEK293 cells. (B) Immunoblotting of phosphoPDPK1, total PDPK1 in untreated and dabrafenib (Dab) and trametinib–treated patient derived ATC and normal thyroid tissues using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to normal thyroid tissue. (C–D) Dose-dependent inhibition of cell proliferation with BX795 treatment in 8505C and SW1736 cells after 48 h. (E–F) Dose-dependent inhibition of cell proliferation with Dab treatment in 8505C and SW1736 ATC cells after 48 h. (G–H) Analysis of the combination index (CI) using the CompuSyn software for BX795, Dab, and their combination in BRAF V600E–mutant ATC cell lines. CI < 1 indicates synergism, and fa denotes fraction affected. (I–J) The effect of BX795 (2.5 µM), Dab (2.5 µM), and their combination on cellular proliferation in 8505C and SW1736 cells after 48 h. (K–L) Colony-formation assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using ImageJ. (M–N) Cellular migration as measured with a wound-healing assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using the ImageJ software. (O–P) Concentration-dependent effects of BX795 treatment on proliferation of patient-derived ATC cells (ATC01 and ATC02). ATC01 was derived from a treatment-naïve patient tumor positive for BRAF V600E mutation, and ATC02 was derived from a residual tumor in a patient with an exceptional treatment response to Dab and trametinib, and the tumor was positive for BRAF V600E mutation. (Q–R) The effects of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on the proliferation of patient-derived ATC cells (ATC01 and ATC02). (S) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on ATC spheroids in BRAF V600E–mutant in the 8505C and SW1736 cell lines. (T) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on patient-derived ATC spheroids (ATC01 and ATC02). All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
    Braf Mutation Test, supplied by Antech Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf mutation test/product/Antech Diagnostics
    Average 86 stars, based on 1 article reviews
    braf mutation test - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    braf mutations  (Pfizer Inc)
    86
    Pfizer Inc braf mutations
    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring <t>BRAF</t> <t>mutations</t> using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.
    Braf Mutations, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf mutations/product/Pfizer Inc
    Average 86 stars, based on 1 article reviews
    braf mutations - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    idylla nras braf mutation test cartridges  (Biocartis)
    86
    Biocartis idylla nras braf mutation test cartridges
    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring <t>BRAF</t> <t>mutations</t> using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.
    Idylla Nras Braf Mutation Test Cartridges, supplied by Biocartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/idylla nras braf mutation test cartridges/product/Biocartis
    Average 86 stars, based on 1 article reviews
    idylla nras braf mutation test cartridges - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    braf codon 600 mutation detection  (Pyrosequencing Inc)
    86
    Pyrosequencing Inc braf codon 600 mutation detection
    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring <t>BRAF</t> <t>mutations</t> using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.
    Braf Codon 600 Mutation Detection, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf codon 600 mutation detection/product/Pyrosequencing Inc
    Average 86 stars, based on 1 article reviews
    braf codon 600 mutation detection - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    thxid braf assay mutation status output  (Pyrosequencing Inc)
    86
    Pyrosequencing Inc thxid braf assay mutation status output
    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring <t>BRAF</t> <t>mutations</t> using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.
    Thxid Braf Assay Mutation Status Output, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/thxid braf assay mutation status output/product/Pyrosequencing Inc
    Average 86 stars, based on 1 article reviews
    thxid braf assay mutation status output - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    braf v600 mutation  (Novartis)
    86
    Novartis braf v600 mutation
    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring <t>BRAF</t> <t>mutations</t> using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.
    Braf V600 Mutation, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf v600 mutation/product/Novartis
    Average 86 stars, based on 1 article reviews
    braf v600 mutation - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and A375 S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).

    Journal: International Journal of Molecular Sciences

    Article Title: Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

    doi: 10.3390/ijms26199794

    Figure Lengend Snippet: Phosphorylation status of MEK, ERK and RSK. ( A ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 S and A375 S cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. ( B ) Western blot analysis of p-MEK/MEK, p-ERK/ERK and p-RSK/RSK in SKMel19 R and A375 R cells. GAPDH was used as a reference protein, and the samples were loaded on a 10% SDS polyacrylamide gel. Cells were treated for 24 h with 5 µM PLX4032 or 5 µM GDC0994. DMSO treatment was used as a control sample. (* unspecifc off target band).

    Article Snippet: The BRAF V600E -mutated melanoma cell lines A375 and SKMel19 were purchased from ATCC (LGC, Wesel, Germany), while Mel1617 and 451LU were kindly provided by M. Herlyn (The Wistar Institute, Philadelphia, PA, USA) [ ].

    Techniques: Phospho-proteomics, Western Blot, Control

    Cell viability and cell cycle. Effects of the combination of ERKi/BRAFi on the viability ( A , B ) and cell cycle ( C ) of melanoma cells. ( A ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) of three independent experiments, each measured in quadruplicate and normalized to the untreated control. ( B ) Shown is the synergism analysis of 451LU (S and R), Mel1617 (S and R) and A375 (S and R) treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. (red = antagonistic, green = synergistic). ( C ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with PLX4032 (1 or 5 µM), GDC0994 (1 and 5 µM) and the combination (1 µM + 1 µM or 5 µM + 5 µM) for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate.

    Journal: International Journal of Molecular Sciences

    Article Title: Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

    doi: 10.3390/ijms26199794

    Figure Lengend Snippet: Cell viability and cell cycle. Effects of the combination of ERKi/BRAFi on the viability ( A , B ) and cell cycle ( C ) of melanoma cells. ( A ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) of three independent experiments, each measured in quadruplicate and normalized to the untreated control. ( B ) Shown is the synergism analysis of 451LU (S and R), Mel1617 (S and R) and A375 (S and R) treated with BRAFi (PLX4032) (up to 20 µM), ERKi (GDC0994) (up to 20 µM) and the combination for 72 h. (red = antagonistic, green = synergistic). ( C ) 451LU S, 451LU R, Mel1617 S, Mel1617 R, A375 S and A375 R cells were treated with PLX4032 (1 or 5 µM), GDC0994 (1 and 5 µM) and the combination (1 µM + 1 µM or 5 µM + 5 µM) for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate.

    Article Snippet: The BRAF V600E -mutated melanoma cell lines A375 and SKMel19 were purchased from ATCC (LGC, Wesel, Germany), while Mel1617 and 451LU were kindly provided by M. Herlyn (The Wistar Institute, Philadelphia, PA, USA) [ ].

    Techniques: Control, Staining, Flow Cytometry

    Colony formation assay. ( A ) The cell lines 451LU S, 451LU R, Mel1617 S and Mel1617 R and ( B ) the cell lines A375 S, A735 R, SKMel19 S and SKMel19 R were seeded and then treated for 10 consecutive days with PLX4032 (5 µM), GDC0994 (5 µM) or the combination. The colonies were fixed with 4% paraformaldehyde visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Journal: International Journal of Molecular Sciences

    Article Title: Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

    doi: 10.3390/ijms26199794

    Figure Lengend Snippet: Colony formation assay. ( A ) The cell lines 451LU S, 451LU R, Mel1617 S and Mel1617 R and ( B ) the cell lines A375 S, A735 R, SKMel19 S and SKMel19 R were seeded and then treated for 10 consecutive days with PLX4032 (5 µM), GDC0994 (5 µM) or the combination. The colonies were fixed with 4% paraformaldehyde visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Article Snippet: The BRAF V600E -mutated melanoma cell lines A375 and SKMel19 were purchased from ATCC (LGC, Wesel, Germany), while Mel1617 and 451LU were kindly provided by M. Herlyn (The Wistar Institute, Philadelphia, PA, USA) [ ].

    Techniques: Colony Assay, Staining

    Effect on double-resistant cell lines. ( A ) Mel1617 RR cells were treated with PLX4032+GDC0973 (up to 20 µM PLX4032 and 5 µM GDC0973), GDC0994 (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) normalized to the untreated control. The bottom panel shows the corresponding synergism analysis. (red = antagonistic, green = synergistic). ( B ) A375 RR and Mel1617 RR cells were treated with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) and the combination thereof for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate. ( C ) The cell lines A375 RR and Mel1617 RR were seeded and then treated for 10 consecutive days with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) or their combination. The colonies were fixed with 4% paraformaldehyde and visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Journal: International Journal of Molecular Sciences

    Article Title: Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

    doi: 10.3390/ijms26199794

    Figure Lengend Snippet: Effect on double-resistant cell lines. ( A ) Mel1617 RR cells were treated with PLX4032+GDC0973 (up to 20 µM PLX4032 and 5 µM GDC0973), GDC0994 (up to 20 µM) and the combination for 72 h. Measured is the viability of treated cells compared to the DMSO-treated controls. Shown are the mean values with standard deviations (SDs) normalized to the untreated control. The bottom panel shows the corresponding synergism analysis. (red = antagonistic, green = synergistic). ( B ) A375 RR and Mel1617 RR cells were treated with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) and the combination thereof for 72 h. The cell cycle after PI staining was measured by flow cytometry. Shown are the mean values of each cell cycle fraction with SDs of three independent experiments, each measured in triplicate. ( C ) The cell lines A375 RR and Mel1617 RR were seeded and then treated for 10 consecutive days with PLX4032 (1 µM), GDC0994 (1 µM), GDC0973 (0.1 µM) or their combination. The colonies were fixed with 4% paraformaldehyde and visualized by staining with a 0.1% Coomassie Brilliant Blue solution (Bio-Rad) containing 30% methanol and 10% acetic acid.

    Article Snippet: The BRAF V600E -mutated melanoma cell lines A375 and SKMel19 were purchased from ATCC (LGC, Wesel, Germany), while Mel1617 and 451LU were kindly provided by M. Herlyn (The Wistar Institute, Philadelphia, PA, USA) [ ].

    Techniques: Control, Staining, Flow Cytometry

    (A) Immunobloting of pPDPK1, PDPK1, pMEK, and MEK in thyroid cancer lines: papillary thyroid cancer (PTC, brown color) (TPC1), follicular thyroid cancer (FTC, blue color) (FTC-133 and FTC-236), poorly differentiated thyroid cancer (PDTC, green color) (BCPAP), BRAF wild type anaplastic thyroid cancer (ATC) (red color) (C643 and THJ29T), BRAF V600E–mutant ATC (8505C, SW1736, and THJ16T), and HEK293 cells using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to HEK293 cells. (B) Immunoblotting of phosphoPDPK1, total PDPK1 in untreated and dabrafenib (Dab) and trametinib–treated patient derived ATC and normal thyroid tissues using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to normal thyroid tissue. (C–D) Dose-dependent inhibition of cell proliferation with BX795 treatment in 8505C and SW1736 cells after 48 h. (E–F) Dose-dependent inhibition of cell proliferation with Dab treatment in 8505C and SW1736 ATC cells after 48 h. (G–H) Analysis of the combination index (CI) using the CompuSyn software for BX795, Dab, and their combination in BRAF V600E–mutant ATC cell lines. CI < 1 indicates synergism, and fa denotes fraction affected. (I–J) The effect of BX795 (2.5 µM), Dab (2.5 µM), and their combination on cellular proliferation in 8505C and SW1736 cells after 48 h. (K–L) Colony-formation assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using ImageJ. (M–N) Cellular migration as measured with a wound-healing assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using the ImageJ software. (O–P) Concentration-dependent effects of BX795 treatment on proliferation of patient-derived ATC cells (ATC01 and ATC02). ATC01 was derived from a treatment-naïve patient tumor positive for BRAF V600E mutation, and ATC02 was derived from a residual tumor in a patient with an exceptional treatment response to Dab and trametinib, and the tumor was positive for BRAF V600E mutation. (Q–R) The effects of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on the proliferation of patient-derived ATC cells (ATC01 and ATC02). (S) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on ATC spheroids in BRAF V600E–mutant in the 8505C and SW1736 cell lines. (T) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on patient-derived ATC spheroids (ATC01 and ATC02). All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Journal: bioRxiv

    Article Title: Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

    doi: 10.64898/2026.03.15.711663

    Figure Lengend Snippet: (A) Immunobloting of pPDPK1, PDPK1, pMEK, and MEK in thyroid cancer lines: papillary thyroid cancer (PTC, brown color) (TPC1), follicular thyroid cancer (FTC, blue color) (FTC-133 and FTC-236), poorly differentiated thyroid cancer (PDTC, green color) (BCPAP), BRAF wild type anaplastic thyroid cancer (ATC) (red color) (C643 and THJ29T), BRAF V600E–mutant ATC (8505C, SW1736, and THJ16T), and HEK293 cells using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to HEK293 cells. (B) Immunoblotting of phosphoPDPK1, total PDPK1 in untreated and dabrafenib (Dab) and trametinib–treated patient derived ATC and normal thyroid tissues using β-actin as a loading control. The relative ratio of pPDPK1 to total PDPK1 and pMEK to total MEK is listed below each phospho-protein compared to normal thyroid tissue. (C–D) Dose-dependent inhibition of cell proliferation with BX795 treatment in 8505C and SW1736 cells after 48 h. (E–F) Dose-dependent inhibition of cell proliferation with Dab treatment in 8505C and SW1736 ATC cells after 48 h. (G–H) Analysis of the combination index (CI) using the CompuSyn software for BX795, Dab, and their combination in BRAF V600E–mutant ATC cell lines. CI < 1 indicates synergism, and fa denotes fraction affected. (I–J) The effect of BX795 (2.5 µM), Dab (2.5 µM), and their combination on cellular proliferation in 8505C and SW1736 cells after 48 h. (K–L) Colony-formation assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using ImageJ. (M–N) Cellular migration as measured with a wound-healing assay in 8505C and SW1736 cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. Quantification was performed using the ImageJ software. (O–P) Concentration-dependent effects of BX795 treatment on proliferation of patient-derived ATC cells (ATC01 and ATC02). ATC01 was derived from a treatment-naïve patient tumor positive for BRAF V600E mutation, and ATC02 was derived from a residual tumor in a patient with an exceptional treatment response to Dab and trametinib, and the tumor was positive for BRAF V600E mutation. (Q–R) The effects of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on the proliferation of patient-derived ATC cells (ATC01 and ATC02). (S) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on ATC spheroids in BRAF V600E–mutant in the 8505C and SW1736 cell lines. (T) The effect of treatment with BX795 (2.5 µM), Dab (2.5 µM), or their combination on patient-derived ATC spheroids (ATC01 and ATC02). All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Article Snippet: The BCPAP (homozygous mutated BRAF V600E) cell line was purchased from Leibniz Institute DSMZ (Lower Saxony, Germany).

    Techniques: Western Blot, Mutagenesis, Control, Derivative Assay, Inhibition, Software, Colony Assay, Migration, Wound Healing Assay, Concentration Assay, Standard Deviation

    (A) Mutated BRAF V600E ATC cells (8505C) were treated for 48 h with BX795 (2.5 µM), dabrafenib (Dab) (2.5 µM), or their combination. Then, total and phosphorylated protein levels were measured using mass spectrometry. (A–C) The volcano plots show significantly upregulated proteins in red, significantly downregulated proteins in blue (p < 0.05), and non-significant proteins in gray. The x-axis represents log 2 fold change, and the y-axis shows –log 10 (p-value). The dashed lines indicate thresholds for statistical significance and fold change. (D) The Venn diagrams shows shared and treatment-specific differentially expressed proteins and phosphorylated proteins across the treatment groups (p < 0.05). The overlapping regions represent a conserved core proteomic response, while the non-overlapping regions indicate pathway-specific effects of PDPK1 or BRAF inhibition. (E–G) Gene set enrichment analysis (GSEA) of ranked phosphorylated site changes following BX795 (E), Dab (F), or combination (G) treatment. The bar plots show normalized enrichment scores (NES) for Hallmark Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways. (H) Western blot analysis of the effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment on BRAF V600E–mutant ATC cell lines (8505C and SW1736) after 48 h. pMEK, total MEK, pAKT 308 , total AKT, pPDPK1 S241 , PARP-1, BCL2, and caspase-3 protein levels are shown, with β-actin used as a loading control. (I) Flow cytometry results of Annexin V/PI staining with BX795 (2.5 µM), Dab (2.5 µM), or combination treatment. (J) Western blot analysis of apoptosis regulatory proteins 40 h after treatment. pBAD S112 , BAD, BCL2, pGSK3β Ser9 , GSK3β, and the double-stranded DNA damage marker pH2AX S139 are shown, with β-actin used as a loading control. Protein band density was measured and normalized to β-actin. The phosphorylated to total protein ratios were measured, and the values are listed above the phosphoprotein band. Protein band density of BCL-xL and pH2AX S139 were also measured and normalized to β-actin. (K) Immunoprecipitation of BCL-xL and BCL2 with BAD 30 h after treatment with BX795 and Dab in BRAF V600E–mutant ATC cell lines. Protein band density was measured and normalized to the input protein band. The ratio of immunoprecipitated to total input protein was measured and is listed below the protein blot. P = phosphorylation. The superscript indicates the amino acid phosphorylation site. (L) The heatmap shows z-scored log 2 -transformed abundance of apoptosis-related proteins for the BX795, Dab, and combination treatment groups in 8505C ATC cells. The proteins are displayed in sequential order—BAD, TNFRSF10A, PARP1, FAS, BID, CASP3, CASP8, BAX, CASP9, CASP7, BCL2L1, and BAK1—with hierarchical clustering applied to the rows. (M) The effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on γH2AX foci formation in the 8505C and SW1736 ATC cell lines using immunofluorescence. γH2AX was labelled with Alexa Fluor™ 546 secondary antibody, with DAPI used for nuclear staining. A Zeiss LSM 800 confocal microscope was used to examine the cells (400× magnification). The number of foci per cell was quantified using ImageJ. All data are presented as the mean ± standard error of the mean of 25 cells. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p<0.001; ****p < 0.0001. (N) Western blot analysis of the effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on DNA damage–dependent proteins (pATM, total ATM, pCHK2, Total CHK2, and pCHK1). β-Actin was used as a loading control. (O) Cell cycle analysis after BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h in BRAF V600E–mutant ATC cell lines (8505C and SW1736). Cells were stained with propidium iodide (PI) and analyzed by fluorescence-activated cell sorting. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on the PI-stained DNA content. (P) The effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on DNA repair proteins—cyclin D, cyclin B, pcdc25c, pCDK1, total CDK1, pH3A, H3A, and cyclin A2—by immunoblotting. β-actin was used as a loading control. The ratio of phospho-H3A to total H3A was measured and is listed below the phospho-H3A protein band. All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (Q) Analysis of the effect of combination BX795 (2.5 µM) and Dab (2.5 µM) treatment for 16 h followed by proteasomal degradation inhibition for 6 h (MG132, 10 µM). Protein band density was measured and normalized to β-actin. (R) The heatmap shows z-scored log2-transformed phosphorylation levels of DNA damage response, DNA repair, and cell-cycle regulatory proteins for the BX795, Dab, and combination treatment groups in 8505C ATC cell line. Proteins are displayed in sequential order as RAD50, CDK1, MCM2, PRKDC, RB1, TP53BP1, TP53, XRCC1, XRCC5, LIG1, MDC1, and MSH6, with supervised hierarchical clustering applied to the rows. The color scale represents relative protein levels (red = higher; blue = lower).

    Journal: bioRxiv

    Article Title: Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

    doi: 10.64898/2026.03.15.711663

    Figure Lengend Snippet: (A) Mutated BRAF V600E ATC cells (8505C) were treated for 48 h with BX795 (2.5 µM), dabrafenib (Dab) (2.5 µM), or their combination. Then, total and phosphorylated protein levels were measured using mass spectrometry. (A–C) The volcano plots show significantly upregulated proteins in red, significantly downregulated proteins in blue (p < 0.05), and non-significant proteins in gray. The x-axis represents log 2 fold change, and the y-axis shows –log 10 (p-value). The dashed lines indicate thresholds for statistical significance and fold change. (D) The Venn diagrams shows shared and treatment-specific differentially expressed proteins and phosphorylated proteins across the treatment groups (p < 0.05). The overlapping regions represent a conserved core proteomic response, while the non-overlapping regions indicate pathway-specific effects of PDPK1 or BRAF inhibition. (E–G) Gene set enrichment analysis (GSEA) of ranked phosphorylated site changes following BX795 (E), Dab (F), or combination (G) treatment. The bar plots show normalized enrichment scores (NES) for Hallmark Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways. (H) Western blot analysis of the effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment on BRAF V600E–mutant ATC cell lines (8505C and SW1736) after 48 h. pMEK, total MEK, pAKT 308 , total AKT, pPDPK1 S241 , PARP-1, BCL2, and caspase-3 protein levels are shown, with β-actin used as a loading control. (I) Flow cytometry results of Annexin V/PI staining with BX795 (2.5 µM), Dab (2.5 µM), or combination treatment. (J) Western blot analysis of apoptosis regulatory proteins 40 h after treatment. pBAD S112 , BAD, BCL2, pGSK3β Ser9 , GSK3β, and the double-stranded DNA damage marker pH2AX S139 are shown, with β-actin used as a loading control. Protein band density was measured and normalized to β-actin. The phosphorylated to total protein ratios were measured, and the values are listed above the phosphoprotein band. Protein band density of BCL-xL and pH2AX S139 were also measured and normalized to β-actin. (K) Immunoprecipitation of BCL-xL and BCL2 with BAD 30 h after treatment with BX795 and Dab in BRAF V600E–mutant ATC cell lines. Protein band density was measured and normalized to the input protein band. The ratio of immunoprecipitated to total input protein was measured and is listed below the protein blot. P = phosphorylation. The superscript indicates the amino acid phosphorylation site. (L) The heatmap shows z-scored log 2 -transformed abundance of apoptosis-related proteins for the BX795, Dab, and combination treatment groups in 8505C ATC cells. The proteins are displayed in sequential order—BAD, TNFRSF10A, PARP1, FAS, BID, CASP3, CASP8, BAX, CASP9, CASP7, BCL2L1, and BAK1—with hierarchical clustering applied to the rows. (M) The effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on γH2AX foci formation in the 8505C and SW1736 ATC cell lines using immunofluorescence. γH2AX was labelled with Alexa Fluor™ 546 secondary antibody, with DAPI used for nuclear staining. A Zeiss LSM 800 confocal microscope was used to examine the cells (400× magnification). The number of foci per cell was quantified using ImageJ. All data are presented as the mean ± standard error of the mean of 25 cells. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p<0.001; ****p < 0.0001. (N) Western blot analysis of the effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on DNA damage–dependent proteins (pATM, total ATM, pCHK2, Total CHK2, and pCHK1). β-Actin was used as a loading control. (O) Cell cycle analysis after BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h in BRAF V600E–mutant ATC cell lines (8505C and SW1736). Cells were stained with propidium iodide (PI) and analyzed by fluorescence-activated cell sorting. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on the PI-stained DNA content. (P) The effect of BX795 (2.5 µM), Dab (2.5 µM), or combination treatment for 16 h on DNA repair proteins—cyclin D, cyclin B, pcdc25c, pCDK1, total CDK1, pH3A, H3A, and cyclin A2—by immunoblotting. β-actin was used as a loading control. The ratio of phospho-H3A to total H3A was measured and is listed below the phospho-H3A protein band. All data are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (Q) Analysis of the effect of combination BX795 (2.5 µM) and Dab (2.5 µM) treatment for 16 h followed by proteasomal degradation inhibition for 6 h (MG132, 10 µM). Protein band density was measured and normalized to β-actin. (R) The heatmap shows z-scored log2-transformed phosphorylation levels of DNA damage response, DNA repair, and cell-cycle regulatory proteins for the BX795, Dab, and combination treatment groups in 8505C ATC cell line. Proteins are displayed in sequential order as RAD50, CDK1, MCM2, PRKDC, RB1, TP53BP1, TP53, XRCC1, XRCC5, LIG1, MDC1, and MSH6, with supervised hierarchical clustering applied to the rows. The color scale represents relative protein levels (red = higher; blue = lower).

    Article Snippet: The BCPAP (homozygous mutated BRAF V600E) cell line was purchased from Leibniz Institute DSMZ (Lower Saxony, Germany).

    Techniques: Mass Spectrometry, Inhibition, Protein-Protein interactions, Western Blot, Mutagenesis, Control, Flow Cytometry, Staining, Marker, Immunoprecipitation, Phospho-proteomics, Transformation Assay, Immunofluorescence, Microscopy, Cell Cycle Assay, Fluorescence, FACS, Standard Deviation

    Mutated BRAF V600E cell were treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. (A) Total cellular ROS was measured using the DCFH-DA fluorescent dye and quantified with flow cytometry. (B) Mitochondrial superoxide was measured based on MitoSOX red fluorescence, quantified with flow cytometry. (C–D) The mitochondrial content was assessed by MitoTracker green fluorescence, as quantified by flow cytometry and visualized with live-cell confocal microscopy (Zeiss LSM 800, 400× magnification). (E) The mitochondrial membrane potential was evaluated by TMRM (100 nM) fluorescence and analyzed by flow cytometry. (F) The oxygen consumption rate (OCR) was measured using a Seahorse analyzer with sequential injections of oligomycin (Oligo), 2,4-dinitrophenol (DNP), and antimycin A plus rotenone (Rot+AA). The data were normalized to the total protein content, and maximal respiration and adenosine triphosphate (ATP)-linked respiration were quantified accordingly. (G) The heatmap shows z-scored log 2 -transformed abundance of proteins associated with mitochondrial oxidative phosphorylation, the tricarboxylic acid (TCA) cycle, mitochondrial ribosomal, transport, and mitochondrial dynamics–associated proteins in 8505C ATC cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. The proteins include representatives of electron transport chain complexes I–V (NDUF subunits, SDHA–D, UQCRC1/2, COX subunits, and ATP5 subunits), TCA cycle enzymes (IDH1, IDH2, IDH3, FH, OGDH, DLST, CS, MDH2, and PDHA1/PDHB), mitochondrial transport and structure (TOMM20, TIMM23, VDAC1–3, MFN1, OPA1, DNM1L), and mitochondrial genome maintenance (TFAM). Hierarchical clustering was applied to the rows. The color scale represents relative protein abundance (red = higher; blue = lower). All data are expressed as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Journal: bioRxiv

    Article Title: Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

    doi: 10.64898/2026.03.15.711663

    Figure Lengend Snippet: Mutated BRAF V600E cell were treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. (A) Total cellular ROS was measured using the DCFH-DA fluorescent dye and quantified with flow cytometry. (B) Mitochondrial superoxide was measured based on MitoSOX red fluorescence, quantified with flow cytometry. (C–D) The mitochondrial content was assessed by MitoTracker green fluorescence, as quantified by flow cytometry and visualized with live-cell confocal microscopy (Zeiss LSM 800, 400× magnification). (E) The mitochondrial membrane potential was evaluated by TMRM (100 nM) fluorescence and analyzed by flow cytometry. (F) The oxygen consumption rate (OCR) was measured using a Seahorse analyzer with sequential injections of oligomycin (Oligo), 2,4-dinitrophenol (DNP), and antimycin A plus rotenone (Rot+AA). The data were normalized to the total protein content, and maximal respiration and adenosine triphosphate (ATP)-linked respiration were quantified accordingly. (G) The heatmap shows z-scored log 2 -transformed abundance of proteins associated with mitochondrial oxidative phosphorylation, the tricarboxylic acid (TCA) cycle, mitochondrial ribosomal, transport, and mitochondrial dynamics–associated proteins in 8505C ATC cells treated with BX795 (2.5 µM), Dab (2.5 µM), or their combination. The proteins include representatives of electron transport chain complexes I–V (NDUF subunits, SDHA–D, UQCRC1/2, COX subunits, and ATP5 subunits), TCA cycle enzymes (IDH1, IDH2, IDH3, FH, OGDH, DLST, CS, MDH2, and PDHA1/PDHB), mitochondrial transport and structure (TOMM20, TIMM23, VDAC1–3, MFN1, OPA1, DNM1L), and mitochondrial genome maintenance (TFAM). Hierarchical clustering was applied to the rows. The color scale represents relative protein abundance (red = higher; blue = lower). All data are expressed as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Article Snippet: The BCPAP (homozygous mutated BRAF V600E) cell line was purchased from Leibniz Institute DSMZ (Lower Saxony, Germany).

    Techniques: Flow Cytometry, Fluorescence, Confocal Microscopy, Membrane, Transformation Assay, Phospho-proteomics, Quantitative Proteomics, Standard Deviation

    (A) Time-dependent effect of combination BX795 and Dab treatment based on propidium iodide (PI) staining, showing the proportion of cells arrested in the G2/M phase. Cells were stained with PI and analyzed by fluorescence-activated cell sorting. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (B) Intracellular ROS levels were measured using DCFH-DA staining and analyzed by flow cytometry. The results are presented as the mean ± standard deviation. (C–E) The effects of N -acetyl cysteine (NAC) (5 mM) on combination treatment–induced responses in BRAF V600E–mutant ATC cell lines. (C) ROS generation was analyzed by DCFH-DA staining and is presented as the mean ± standard deviation. (D) Apoptosis was assessed based on Annexin V/PI staining. (E) Immunoblot analysis of PARP-1 cleavage using β-actin as a loading control. The densitometric quantification of cleaved vs pro-PARP cleavage in relation to loading control is shown below the bands. (F) The effect of the mitochondrial ROS scavenger MitoQ on combination treatment–induced G2/M arrest in BRAF V600E–mutant ATC cell lines. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on PI staining. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (G–H) The impact of CHK2 phosphorylation inhibitor BML-277 (ML277) on combination BX795 and Dab treatment-induced. (G) Cell cycle arrest was analyzed by PI staining and flow cytometry. (H) Antiproliferative effect in BRAF V600E–mutant ATC cells. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on PI staining. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (I) Apoptosis was measured with Annexin V/PI staining and flow cytometry. The results are presented as mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Journal: bioRxiv

    Article Title: Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

    doi: 10.64898/2026.03.15.711663

    Figure Lengend Snippet: (A) Time-dependent effect of combination BX795 and Dab treatment based on propidium iodide (PI) staining, showing the proportion of cells arrested in the G2/M phase. Cells were stained with PI and analyzed by fluorescence-activated cell sorting. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (B) Intracellular ROS levels were measured using DCFH-DA staining and analyzed by flow cytometry. The results are presented as the mean ± standard deviation. (C–E) The effects of N -acetyl cysteine (NAC) (5 mM) on combination treatment–induced responses in BRAF V600E–mutant ATC cell lines. (C) ROS generation was analyzed by DCFH-DA staining and is presented as the mean ± standard deviation. (D) Apoptosis was assessed based on Annexin V/PI staining. (E) Immunoblot analysis of PARP-1 cleavage using β-actin as a loading control. The densitometric quantification of cleaved vs pro-PARP cleavage in relation to loading control is shown below the bands. (F) The effect of the mitochondrial ROS scavenger MitoQ on combination treatment–induced G2/M arrest in BRAF V600E–mutant ATC cell lines. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on PI staining. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (G–H) The impact of CHK2 phosphorylation inhibitor BML-277 (ML277) on combination BX795 and Dab treatment-induced. (G) Cell cycle arrest was analyzed by PI staining and flow cytometry. (H) Antiproliferative effect in BRAF V600E–mutant ATC cells. The DNA content was measured, 2N (diploid) and 4N (tetraploid), based on PI staining. The results are presented as the mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (I) Apoptosis was measured with Annexin V/PI staining and flow cytometry. The results are presented as mean ± standard deviation. Statistical significance is indicated as ns = nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

    Article Snippet: The BCPAP (homozygous mutated BRAF V600E) cell line was purchased from Leibniz Institute DSMZ (Lower Saxony, Germany).

    Techniques: Staining, Fluorescence, FACS, Standard Deviation, Flow Cytometry, Mutagenesis, Western Blot, Control, Phospho-proteomics

    Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring BRAF mutations using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.

    Journal: Journal of Gastrointestinal Oncology

    Article Title: Molecular and clinical registry of Chilean patients diagnosed with BRAF-mutated colorectal cancer

    doi: 10.21037/jgo-2025-115

    Figure Lengend Snippet: Cox proportional hazards model covariate analysis. This analysis assessed survival outcomes in a cohort of colorectal cancer patients harboring BRAF mutations using a Cox proportional hazards model. Sex and pathological stage (stage II) were included as covariates. The model was applied to a sample of 18 patients, incorporating 7 of the 9 distinct event times (deaths). Additionally, the Aalen additive regression model was employed using test-based weights to further evaluate covariate effects over time. M, male; SE, standard error.

    Article Snippet: ; grant No. 11220563 to I.N.R.), Starup BEACON-Chile from FONDECYT (grant No. SUC250215 to B.G.B.), and Pfizer programs which are Molecular Clinical Registry of Patients Diagnosed with Colon Cancer and BRAF mutations ( No. 77605465 ) and Pfizer Investigator Sponsored Research (grant #ISR CA209-8F3 to M.G.).

    Techniques: